Arterial Remodeling Technologies Signs Structured Buyout Agreement With Terumo Corporation, Validating ART’s Next-Gen Bioresorbable Scaffold

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Privately held Arterial Remodeling Technologies (‘ART’) announced today that it has signed a structured buyout agreement with Terumo Corporation. Under the agreement, ART and Terumo Corporation will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART Security Holders will retain full ownership of the ART bioresorbable scaffold technology for all other indications. Terumo Corporation will make staged R&D investments in ART and ART has granted an exclusive option to Terumo Corporation to purchase ART at any time prior to the initiation of clinical trials.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC